ULTA vs. APLS
ULTA (Ulta Beauty, Inc.) and APLS (Apellis Pharmaceuticals, Inc.) are both stocks. ULTA operates in Specialty Retail (Consumer Cyclical), while APLS operates in Biotechnology (Healthcare). Over the past 5 years, ULTA returned 7.61%/yr vs -1.50%/yr for APLS. At a 0.19 correlation, their price movements are largely independent.
Performance
ULTA vs. APLS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ULTA achieves a -22.12% return, which is significantly lower than APLS's 63.34% return.
ULTA
- 1D
- -4.78%
- 1M
- -9.03%
- YTD
- -22.12%
- 6M
- -13.46%
- 1Y
- -0.40%
- 3Y*
- 3.71%
- 5Y*
- 7.61%
- 10Y*
- 7.13%
APLS
- 1D
- 0.00%
- 1M
- 0.15%
- YTD
- 63.34%
- 6M
- 93.08%
- 1Y
- 118.01%
- 3Y*
- -22.49%
- 5Y*
- -1.50%
- 10Y*
- —
ULTA vs. APLS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ULTA Ulta Beauty, Inc. | -22.12% | 39.11% | -11.24% | 4.46% | 13.76% | 43.59% | 13.44% | 3.39% | 9.47% | 12.28% |
APLS Apellis Pharmaceuticals, Inc. | 63.34% | -21.28% | -46.69% | 15.76% | 9.37% | -17.34% | 86.81% | 132.15% | -39.22% | 54.67% |
Correlation
The correlation between ULTA and APLS is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Nov 10, 2017 | 0.19 |
Fundamentals
ULTA:
$26.57
APLS:
$1.41
ULTA:
17.73
APLS:
29.10
ULTA:
1.66
APLS:
3.77
ULTA:
$12.71B
APLS:
$1.03B
ULTA:
$5.00B
APLS:
$920.13M
ULTA:
$1.81B
APLS:
$176.85M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ULTA vs. APLS — Risk / Return Rank
ULTA
APLS
ULTA vs. APLS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ulta Beauty, Inc. (ULTA) and Apellis Pharmaceuticals, Inc. (APLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ULTA | APLS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.00 | ||
| Sortino ratioReturn per unit of downside risk | -3.45 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.58 | -0.55 |
| Calmar ratioReturn relative to maximum drawdown | -0.01 | 3.37 | -3.38 |
| Martin ratioReturn relative to average drawdown | -0.03 | 7.45 | -7.48 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ULTA | APLS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.01 | 0.99 | -1.00 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | -0.02 | +0.24 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.19 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.16 | +0.19 |
Drawdowns
ULTA vs. APLS - Drawdown Comparison
The maximum ULTA drawdown since its inception was -87.89%, which is greater than APLS's maximum drawdown of -82.47%. Use the drawdown chart below to compare losses from any high point for ULTA and APLS.
Loading charts...
Drawdown Indicators
| ULTA | APLS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.89% | -82.47% | -5.42% |
Max Drawdown (1Y)Largest decline over 1 year | -33.33% | -43.53% | +10.20% |
Max Drawdown (3Y)Largest decline over 3 years | -44.56% | -82.47% | +37.91% |
Max Drawdown (5Y)Largest decline over 5 years | -44.56% | -82.47% | +37.91% |
Max Drawdown (10Y)Largest decline over 10 years | -64.92% | — | — |
Current DrawdownCurrent decline from peak | -33.33% | -56.03% | +22.70% |
Average DrawdownAverage peak-to-trough decline | -20.79% | -37.13% | +16.34% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.98% | 19.63% | -6.65% |
Volatility
ULTA vs. APLS - Volatility Comparison
Ulta Beauty, Inc. (ULTA) has a higher volatility of 9.57% compared to Apellis Pharmaceuticals, Inc. (APLS) at 0.54%. This indicates that ULTA's price experiences larger fluctuations and is considered to be riskier than APLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ULTA | APLS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.57% | 0.54% | +9.03% |
Volatility (6M)Calculated over the trailing 6-month period | 27.65% | 91.44% | -63.79% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.15% | 147.98% | -114.83% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 34.28% | 91.01% | -56.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 38.30% | 83.60% | -45.30% |
Dividends
ULTA vs. APLS - Dividend Comparison
Neither ULTA nor APLS has paid dividends to shareholders.
Financials
ULTA vs. APLS - Financials Comparison
This section allows you to compare key financial metrics between Ulta Beauty, Inc. and Apellis Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ULTA vs. APLS - Profitability Comparison
ULTA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ulta Beauty, Inc. reported a gross profit of 1.27B and revenue of 3.16B. Therefore, the gross margin over that period was 40.1%.
APLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a gross profit of 151.46M and revenue of 192.01M. Therefore, the gross margin over that period was 78.9%.
ULTA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ulta Beauty, Inc. reported an operating income of 448.26M and revenue of 3.16B, resulting in an operating margin of 14.2%.
APLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported an operating income of 26.47M and revenue of 192.01M, resulting in an operating margin of 13.8%.
ULTA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ulta Beauty, Inc. reported a net income of 340.47M and revenue of 3.16B, resulting in a net margin of 10.8%.
APLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a net income of 18.66M and revenue of 192.01M, resulting in a net margin of 9.7%.
Frequently Asked Questions
ULTA and APLS have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ULTA has higher volatility (9.57%) compared to APLS (0.54%). In terms of maximum drawdown, ULTA dropped -87.89% vs APLS's -82.47%.
APLS currently has the higher Sharpe Ratio (0.99 vs -0.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ULTA and APLS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer